Literature DB >> 971545

A perspective on aldosterone abnormalities.

E G Biglieri.   

Abstract

Not all the varied clinical disorders in which aldosterone and the mineralocorticoid hormones are involved have been reviewed. Only those disorders in which the mineralocorticoid hormones and their regulatory factors are the principal cause of the biochemical and clinical abnormalities have been examined. These are many and varied. Appreciation of the extent and magnitude of their involvement in the regulation of blood pressure, body fluids, and electrolyte composition continues to grow. The major direct clinical impact of the mineralocorticoid hormones appears to be in two areas: hypertension and potassium homeostasis. Their part in the mosaic of hypertension is established in primary hyperaldosteronism, but they also appear to affect and modify the hypertensive process in primary or essential hypertension. The probe continues. Hypoaldosteronism is more than the rare occurrence associated with Addison's disease. It may be the clue to the presence of nonaldosterone mineralocorticoid excess syndromes, and is obviously of critical importance in an increasing number of patients with chronic renal failure of varied aetiologies.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 971545     DOI: 10.1111/j.1365-2265.1976.tb01968.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  3 in total

1.  Spontaneous sexual development and menarche in a female with 17 alpha-hydroxylase deficiency.

Authors:  P N Singhellakis; D Panidis; J Papadimas; H Demertzi; A Tsourdis; F Sotsiou; D G Ikkos
Journal:  J Endocrinol Invest       Date:  1986-04       Impact factor: 4.256

Review 2.  The renin-angiotensin-aldosterone system. Past, present and future.

Authors:  P Vecsei; E Hackenthal; D Ganten
Journal:  Klin Wochenschr       Date:  1978

3.  Adrenalectomy in primary aldosteronism: a long-term follow-up study in 52 patients.

Authors:  G Favia; F Lumachi; V Scarpa; D F D'Amico
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.